This year’s Nathan S. Greenfield Family Lecture, titled 'Targeted Protein Degradation as a Novel Therapeutic Strategy,' was held on September 3, 2024, at 3 PM in Wolstein Auditorium, featuring Shaomeng Wang, PhD, from the University of Michigan Medical School.
Dr. Wang is currently Warner-Lambert/Parke-Davis Professor in Medicine, Professor of 
Dr. Wang obtained his BS degree in Chemistry from Peking University in 1986 and PhD degree in Chemistry from ÐÇ¿Õ´«Ã½ in 1993.
Dr. Wang was the former Editor-in-Chief for Journal of Medicinal Chemistry, a premier international journal in medicinal chemistry and drug discovery by the American Chemical Society and serves on the editorial board for several international journals.
Dr. Shaomeng Wang has published 360 peer-reviewed papers (H-index = 107) and an inventor of 73 issued US patents and hundreds of international patents. He was elected as Fellow of the National Academy of Inventors in 2014 and as Fellow of the American Association for the Advancement of Science (AAAS) in 2019, was inducted into the Hall of Fame of the Division of Medicinal Chemistry of American Chemical Society in 2020.
Dr. Wang was the 2014 University of Michigan Distinguished Innovator, the recipient of the 2023 Distinguished Faculty Lectureship in Biomedical Research Award of the University of Michigan, the ACS Medicinal Chemistry Awardee in 2020, and received the 2024 ÐÇ¿Õ´«Ã½ College of LSA Distinguished Professional Achievement Award.
In addition to his academic role, Dr Wang is a co-founder of Ascenta Therapeutics, Ascentage Pharma (HK:6855), Oncopia Therapeutics (Acquired by Roivant Sciences: NASDAQ:ROIV), Medsyn Biopharma, which were established to develop innovative anticancer medicines with technologies licensed mainly from the University of Michigan. Dr. Wang has advanced 10 novel anticancer drugs into Phase 1-3 clinical development.
If you want to know more about Dr. Wang and his recent lab work, please visit .
Source
VanDyke, N. (2024). Wang lab. Wang Lab.